



# The IMI2 Ebola+ programme

**Angela Wittelsberger, PhD**  
IMI Scientific Officer

# Background

- Ebola virus disease (EVD) – rare but deadly
- Causes severe, usually lethal haemorrhagic fever
- Like other filoviruses, transmitted from person to person via contact with bodily fluids
- Current W. Africa outbreak unprecedented in scale and geographic spread (over 13 000 cases and approx. 5 000 deaths)

# Challenges


- No licensed vaccines
- No licensed treatments
- No good diagnostic tests
- Rapid scaling up of candidate vaccine doses needed for current epidemic is difficult
- Current vaccine candidates require very cold temperatures for stability during transport
- Deployment (reaching those most in need) is challenging
- Adherence to vaccination regimens is challenging
- Range of products needed for current and future outbreaks

# Ebola+ programme overview

- Addresses **Ebola & other filoviral haemorrhagic fevers** (e.g. Marburg)
- Designed to respond to both **current and future** outbreaks
- **Complements** other European and international efforts
- Will **mobilise** forces across companies, sectors, and disciplines
- Covers **entire innovation cycle**: from early development to patient access
- Will be **fine-tuned** in response to evolution of epidemics, changes in regulatory landscape, progress of other initiatives, stakeholder input, participation of additional contributors

# Ebola+ programme overview

## IMI2 Ebola and other Filoviral Haemorrhagic Fevers (Ebola+) Programme



# Ebola+ programme: Call 1

## Topics

- Topic 1: Vaccine development Phase I, II, and III
- Topic 2: Manufacturing capability
- Topic 3: Stability of vaccines during transport and storage
- Topic 4: Deployment and compliance of vaccination regimens
- Topic 5: Rapid diagnostic tests

## Budget

- Indicative IMI financial contribution: up to €140 million
- Indicative contribution by EFPIA companies: approx. €140 million

**Deadline: 1 December**

# Ebola+ possible future Calls

## Treatments

- Immunotherapy
- Antiviral development and repurposing

## Vaccines

- Formulations for cold chain
- Multivalent filovirus vaccine development

## Diagnostics

- Rapid diagnostic tests – long term